{"id":"nct:NCT07794579","kind":"trial","title":"A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity","authors":["Eli Lilly and Company"],"author_count":1,"year":2026,"published":"2026-08-31","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07794579","source_url":"https://clinicaltrials.gov/study/NCT07794579","archive_url":"https://space-kitty.com/papers/nct:NCT07794579","updated":"2026-10-08","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Overweight","Prediabetic State","Prehypertension","Obesity, Abdominal"],"details":{"acronym":"ATTAIN-NOW","status":"RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":2001,"sponsor":"Eli Lilly and Company","conditions":["Overweight","Prediabetic State","Prehypertension","Obesity, Abdominal"],"interventions":["DRUG: Orforglipron","DRUG: Placebo"],"start_date":"2026-08-26","start_date_type":"ACTUAL","primary_completion_date":"2029-08-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[{"slug":"glp1-metabolic","title":"GLP-1 & Incretin Therapies: State of the Field (October 2026)","url":"https://space-kitty.com/dossiers/glp1-metabolic"}]}